MedVellum
MedVellum
Back to Library
Gastroenterology
Colorectal Surgery
Internal Medicine

Crohn's Disease

High EvidenceUpdated: 2025-12-22

On This Page

Red Flags

  • Bowel obstruction
  • Fistulae (enterocutaneous, enteroenteric, enterovesical)
  • Intra-abdominal abscess
  • Perforation
  • Toxic megacolon (rare)
  • Severe malnutrition
Overview

Crohn's Disease

1. Topic Overview

Summary

Crohn's disease is a chronic, relapsing inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to anus, though it most commonly involves the terminal ileum and colon. Unlike ulcerative colitis, Crohn's causes transmural (full-thickness) inflammation, leading to characteristic complications including strictures, fistulae, and abscesses. Inflammation is typically discontinuous ("skip lesions"). The aetiology involves genetic susceptibility, environmental triggers, and immune dysregulation. Treatment aims to induce and maintain remission, prevent complications, and improve quality of life. First-line therapies include corticosteroids for induction and immunomodulators (thiopurines, methotrexate) or biologics (anti-TNF, anti-integrin, anti-IL-12/23) for maintenance.

Key Facts

  • Definition: Chronic transmural IBD affecting any part of GI tract
  • Age of Onset: Bimodal — 15-30 years and 50-70 years
  • Location: Terminal ileum (most common), colon, ileocolonic, upper GI
  • Pattern: Skip lesions, transmural inflammation, cobblestoning
  • Histology: Non-caseating granulomas (pathognomonic but not always present)
  • Complications: Strictures, fistulae, abscesses
  • Surgery: Not curative; high recurrence rate

Clinical Pearls

"Crohn's — Mouth to Anus, Skip Lesions, Transmural": Remember the key distinguishing features from UC.

"If Perianal Disease, Think Crohn's": Perianal fistulae and abscesses are common in Crohn's, not UC.

"Anti-TNF Changes the Game": Biologics have transformed Crohn's management, achieving mucosal healing and reducing surgery.

Why This Matters Clinically

Crohn's disease is a lifelong condition causing significant morbidity. Early aggressive treatment can prevent complications and improve long-term outcomes. A multidisciplinary approach involving gastroenterology, surgery, dietetics, and psychology is essential.


2. Epidemiology

Incidence & Prevalence

  • Incidence: 5-10 per 100,000 per year (developed countries)
  • Prevalence: 100-300 per 100,000
  • Trend: Increasing worldwide, especially in developing countries
  • Age of Onset: Bimodal — peak 15-30 years; second peak 50-70 years

Demographics

FactorDetails
AgeBimodal distribution
SexSlight female predominance
EthnicityHigher in Caucasians; rising in Asia
SmokingINCREASES risk (unlike UC)

Risk Factors

FactorEffect
GeneticsNOD2/CARD15 mutations; family history
Smoking2x risk; worsens disease
AppendicectomyPossible protective effect
DietWestern diet associated
InfectionsPossible trigger
Antibiotics in childhoodAssociated with IBD

3. Pathophysiology

Mechanism

Step 1: Genetic Susceptibility

  • NOD2/CARD15, IL23R, ATG16L1 mutations
  • Impaired bacterial handling

Step 2: Environmental Trigger

  • Smoking, diet, infections, altered microbiome

Step 3: Immune Dysregulation

  • Loss of tolerance to gut microbiota
  • Th1/Th17 response predominates
  • TNF-α, IL-12, IL-23, IFN-γ elevated

Step 4: Transmural Inflammation

  • Full-thickness bowel involvement
  • Granuloma formation
  • Fibrosis, strictures
  • Sinus tracts, fistulae

Crohn's vs Ulcerative Colitis

FeatureCrohn's DiseaseUlcerative Colitis
LocationMouth to anus (terminal ileum most common)Colon only (rectum to proximal)
DistributionSkip lesionsContinuous from rectum
DepthTransmuralMucosal
HistologyGranulomas, transmural inflammationCrypt abscesses, goblet cell depletion
StricturesCommonRare
FistulaeCommonVery rare
Perianal diseaseCommonRare
SurgeryNot curativeCurative (panproctocolectomy)
SmokingWorsens diseaseProtective

4. Clinical Presentation

Symptoms

Signs

Extra-Intestinal Manifestations

SystemManifestation
JointsPeripheral arthritis, sacroiliitis, ankylosing spondylitis
SkinErythema nodosum, pyoderma gangrenosum
EyesUveitis, episcleritis
HepatobiliaryPSC, gallstones, fatty liver
OralAphthous ulcers
VascularVTE (increased risk)

Red Flags

[!CAUTION] Red Flags — Surgical Emergency:

  • Bowel obstruction (distension, vomiting, absolute constipation)
  • Perforation (acute abdomen, peritonism)
  • Intra-abdominal abscess (fever, mass, sepsis)
  • Toxic megacolon (rare in Crohn's)
  • Massive GI bleeding (rare)

Chronic diarrhoea (often non-bloody)
Common presentation.
Abdominal pain (RLQ, crampy)
Common presentation.
Weight loss, poor appetite
Common presentation.
Fatigue
Common presentation.
Fever, malaise
Common presentation.
Mouth ulcers
Common presentation.
Perianal symptoms (pain, discharge)
Common presentation.
5. Clinical Examination

Structured Approach

General:

  • Nutritional status (weight, BMI)
  • Pallor, clubbing, lymphadenopathy

Abdominal:

  • Tenderness (RIF/RLQ common)
  • Mass (phlegmon, abscess)
  • Scars (previous surgery)
  • Stomas

Perianal:

  • Fistulae, skin tags
  • Abscesses
  • Fissures

Extra-Intestinal:

  • Joints (peripheral arthritis, spine)
  • Skin (erythema nodosum, pyoderma)
  • Eyes (red eye → uveitis/episcleritis)

6. Investigations

First-Line

TestPurposeFindings
FBCAnaemia, thrombocytosisAnaemia common
CRP/ESRInflammationElevated in active disease
AlbuminNutritional statusLow in severe disease
Iron studies, B12, FolateDeficienciesCommon (malabsorption)
LFTsPSC, drug monitoringMay be abnormal
Faecal CalprotectinGut inflammation>250 suggests IBD
Stool MCS + C. diffExclude infectionRule out infectious cause

Imaging

ModalityIndication
MRI Small BowelGold standard for small bowel assessment; strictures, fistulae
CT Abdomen/PelvisAcute presentation; abscess, perforation
MRI PelvisPerianal fistulae assessment
USS AbdomenAbscess screening

Endoscopy

ProcedureFindings
Ileocolonoscopy + biopsiesSkip lesions, cobblestoning, ulcers; histology
OGDUpper GI involvement
Capsule EndoscopySmall bowel if MRI negative and suspicion remains

7. Management

Induction of Remission

SeverityTreatment
Mild-ModerateBudesonide 9mg OD (ileal/right-sided) or Prednisolone 40mg
Moderate-SeverePrednisolone 40mg OD; if fails → anti-TNF
Severe AcuteIV Hydrocortisone; consider infliximab rescue

Maintenance of Remission

ClassExamples
ThiopurinesAzathioprine, Mercaptopurine (check TPMT)
MethotrexateSC/IM weekly
Anti-TNFInfliximab (IV), Adalimumab (SC)
Anti-IntegrinVedolizumab
Anti-IL-12/23Ustekinumab
Anti-IL-23Risankizumab
JAK InhibitorsUpadacitinib (emerging)

Surgery

  • Indications: Strictures, fistulae, abscess, perforation, refractory disease
  • Limited resection with primary anastomosis
  • Not curative (50-70% recurrence)
  • Post-op prophylaxis reduces recurrence

Perianal Disease

  • MRI pelvis for staging
  • Antibiotics (metronidazole + ciprofloxacin)
  • EUA + seton insertion
  • Anti-TNF (infliximab first-line)

8. Complications

Intestinal

ComplicationNotes
StricturesObstruction; endoscopic dilatation or surgery
FistulaeEnterocutaneous, enteroenteric, enterovesical, perianal
AbscessRequires drainage
PerforationSurgical emergency
Colorectal cancerIncreased risk with colonic involvement

Nutritional

  • Malnutrition, weight loss
  • Iron, B12, folate deficiency
  • Vitamin D deficiency
  • Osteoporosis

Treatment-Related

DrugComplications
SteroidsOsteoporosis, diabetes, infection, adrenal suppression
ThiopurinesMyelosuppression, hepatotoxicity, lymphoma (EBV-associated)
MethotrexateHepatotoxicity, myelosuppression, ILD
Anti-TNFSerious infections, TB reactivation, demyelination

9. Prognosis & Outcomes

Natural History

Crohn's disease is a chronic relapsing-remitting condition. Without treatment, most patients experience flares. Up to 80% require surgery within 20 years of diagnosis. Modern biologic therapy has reduced surgical rates.

Outcomes

VariableOutcome
Surgery-free rate at 10 years~50% (improving with biologics)
Recurrence post-surgery50-70% within 5-10 years
MortalitySlightly increased (1.5x general population)

Poor Prognostic Factors

  • Perianal disease
  • Stricturing or penetrating behaviour
  • Young age at onset
  • Smoking
  • Need for steroids at diagnosis
  • Extensive disease

10. Evidence & Guidelines

Key Guidelines

  1. ECCO Guidelines on Crohn's Disease (2023) — European consensus.

  2. NICE NG129: Crohn's Disease (2019) — UK pathway.

Landmark Trials

SONIC Trial (2010) — Combination therapy

  • Infliximab + Azathioprine vs monotherapy
  • Key finding: Combination superior for remission
  • Clinical Impact: Supports combination therapy in anti-TNF-naive patients

UNITI Trials (2016) — Ustekinumab

  • Key finding: Ustekinumab effective for anti-TNF failures
  • Clinical Impact: IL-12/23 inhibition as alternative mechanism

Evidence Strength

InterventionLevelKey Evidence
Anti-TNF for moderate-severe1aACCENT, SONIC
Thiopurines for maintenance1aMeta-analyses
Budesonide for ileal disease1aRCTs

11. Patient/Layperson Explanation

What is Crohn's Disease?

Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation in your digestive tract, usually the small intestine and/or colon. The inflammation can cause pain, diarrhoea, weight loss, and tiredness.

What causes it?

The exact cause isn't known, but it involves your immune system attacking your gut. Genetics, environment, and gut bacteria all play a role. Smoking makes it worse.

What are the symptoms?

  • Diarrhoea (sometimes with blood)
  • Abdominal pain, often on the right side
  • Weight loss
  • Tiredness
  • Mouth ulcers
  • Problems around the bottom (fistulas, abscesses)

How is it treated?

  1. Steroids: To calm flare-ups quickly (short-term only)
  2. Immune-modifying drugs: Azathioprine, methotrexate for long-term control
  3. Biological medicines: Injections or infusions that target specific parts of the immune system
  4. Surgery: Sometimes needed for complications like blockages or abscesses

What to expect

  • Crohn's is a lifelong condition with flares and remissions
  • Most people can live normal lives with treatment
  • Regular check-ups and monitoring are important
  • You may need to adjust treatment over time

When to seek help

See your doctor or IBD team if:

  • Your symptoms get worse
  • You have severe abdominal pain or bloating
  • You can't keep food or fluids down
  • You have a high fever
  • You notice new symptoms

12. References

Primary Guidelines

  1. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4-22. PMID: 31711158

Key Trials

  1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease (SONIC). N Engl J Med. 2010;362(15):1383-1395. PMID: 20393175

  2. NICE. Crohn's disease: management (NG129). 2019. nice.org.uk/guidance/ng129

Further Resources

  • Crohn's & Colitis UK: crohnsandcolitis.org.uk
  • ECCO: ecco-ibd.eu


Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.

Last updated: 2025-12-22

At a Glance

EvidenceHigh
Last Updated2025-12-22

Red Flags

  • Bowel obstruction
  • Fistulae (enterocutaneous, enteroenteric, enterovesical)
  • Intra-abdominal abscess
  • Perforation
  • Toxic megacolon (rare)
  • Severe malnutrition

Clinical Pearls

  • **"Crohn's — Mouth to Anus, Skip Lesions, Transmural"**: Remember the key distinguishing features from UC.
  • **"If Perianal Disease, Think Crohn's"**: Perianal fistulae and abscesses are common in Crohn's, not UC.
  • **"Anti-TNF Changes the Game"**: Biologics have transformed Crohn's management, achieving mucosal healing and reducing surgery.
  • **Red Flags — Surgical Emergency:**
  • - Bowel obstruction (distension, vomiting, absolute constipation)

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines